Skip to main content

Table 4 Adjusted risk ratio and 95% CI for medication effectiveness (algorithm result) (n = 16,305)

From: Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study

Parameter Adjusted risk ratio 95% CI
Drug therapy
 Non-TNF biologics ± DMARDs Reference
 DMARDs 0.58 0.51–0.66
 TNFi ± DMARDs 0.94 0.86–1.03
 Tofacitinib ± DMARDs 0.75 0.42–1.34
Sex (female) 0.94 0.87–1.02
Age 1.01 1.00–1.01
Year of cohort entry
 2011 Reference
 2012 0.87 0.8–0.95
 2013 1.00 0.91–1.1
Oral glucocorticoid use 1 year prior to cohort entry
 No use Reference
 Use of ≤ 7.5 mg/day of prednisone equivalent dose 0.94 0.88–1.02
 Use of > 7.5 mg/day of prednisone equivalent dose 1.07 0.90–1.26
Nonsteroidal anti-inflammatory drug use 1 year prior to cohort entry 0.94 0.88–1.01
Selective COX-2 inhibitors use 1 year prior to cohort entry 0.98 0.88–1.08
Charlson comorbidity index 1 year prior to cohort entry 0.91 0.86–0.95
Infection-related hospitalization 1 year prior to cohort entry 0.84 0.60–1.19
Number of emergency department visits 1 year prior to cohort entry 0.96 0.90–1.01
Number of physician visits 1 year prior to cohort entry 1.00 0.99–1.00
Number of rheumatology visits 1 year prior to cohort entry 1.00 1.00–1.01
Number of hospitalizations 1 year prior to cohort entry 0.97 0.89–1.06
  1. Abbreviations: DMARD Disease-modifying antirheumatic drug, TNFi Tumor necrosis factor inhibitors, COX-2 Cyclooxygenase-2